![]() |
市場調查報告書
商品編碼
2056439
免疫組織化學市場報告:按產品、應用、最終用途和地區分類(2026-2034 年)Immunohistochemistry Market Report by Product (Antibodies, Equipment, Reagents, Kits), Application (Diagnostics, Drug Testing), End Use (Hospitals and Diagnostic Laboratories, Research Institutes, and Others), and Region 2026-2034 |
||||||
2025年,全球免疫組織化學市場規模達30億美元。展望未來,IMARC Group預測,到2034年,該市場規模將達到52億美元,2026年至2034年的複合年成長率為6.02%。慢性病盛行率上升、對個人化醫療的需求不斷成長、診斷技術的顯著進步、醫療基礎設施投資的增加以及人口老化是推動市場成長的主要因素。
慢性病盛行率增加
慢性疾病(包括癌症)發生率的上升推動了對精準診斷和預後工具的需求。免疫組織化學對於檢測癌症和其他疾病的生物標記至關重要,有助於制定精準的診斷和治療方案。世界衛生組織(WHO)發布的數據顯示,2022年全球新增癌症病例約2,000萬例,死亡病例約970萬例。約有5350萬人在確診癌症後存活五年。大約五分之一的人一生中會罹患癌症,約九分之一的男性和十二分之一的女性會死於癌症。領先企業正積極應對這項需求激增的局面,推出更有效的產品和服務。例如,2024年4月,生命科學研究和臨床診斷產品領域的全球領導者Bio-Rad Laboratories, Inc.宣布推出首款超靈敏多重數位PCR檢測產品-ddPLEX ESR1突變檢測試劑盒。此檢測方法擴展了該公司面向腫瘤市場的液滴數位PCR (ddPCR)產品組合。這種高靈敏度、多重突變檢測方法將有助於轉化研究、治療方法選擇和疾病監測。預計這將進一步推動未來幾年免疫組織化學市場的成長。
顯著的技術進步
顯微鏡、染色和數位成像技術的進步顯著提升了免疫組織化學技術的有效性和效率,使其成為組織分析的首選方法。例如,2023年5月,全球領先的醫療技術公司BD(貝克頓·迪金森公司)宣佈在全球推出一款全新的細胞分選系統。該系統融合了兩項突破性技術,使研究人員能夠獲取傳統流式細胞技術實驗無法捕捉到的細胞詳細資訊。 BD CellView影像技術使研究人員能夠查看單一細胞的詳細顯微影像,並透過基於視覺特徵的快速分選,即時檢驗研究結果。 BD SpectalFX技術則實現了全光譜細胞分選,並藉助全新的模組化光學架構和系統識別演算法,顯著提升了性能,使研究人員能夠在簡化的工作流程中開展高參數實驗。
個人化醫療正日益受到關注。
隨著腫瘤學領域個人化醫療的推進,免疫組織化學在識別特定分子標靶和提供針對每位患者個別特徵的客製化治療方面的需求日益成長,有望改善治療效果。例如,2023年6月,全球科學領域的領導者賽默飛世爾科技宣布推出Gibco OncoPro腫瘤類器官培養基試劑盒,這是首個專為培養來自多種癌症適應症的患者來源腫瘤樣組織(癌類器官)而開發的商用培養基。同樣,2023年1月,位於班加羅爾的阿波羅癌症中心開設了印度首個人工智慧驅動的精準腫瘤中心(POC)。這項重大措施將大幅提升腫瘤治療的品質。該中心將充分利用人工智慧的巨大潛力,幫助腫瘤科醫生、患者及其看護者在規定的時間內取得最佳治療效果。這正在對全球免疫組織化學市場的收入產生影響。
The global immunohistochemistry market size reached USD 3.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 5.2 Billion by 2034, exhibiting a growth rate (CAGR) of 6.02% during 2026-2034. The rising prevalence of chronic diseases, the increasing demand for personalized medicines, significant advancements in diagnostic techniques, growing investments in healthcare infrastructure, and the rising aging population are some of the major factors propelling the growth of the market.
Increasing Prevalence of Chronic Diseases
The rising incidence of chronic diseases including cancer is driving the demand for accurate diagnostic and prognostic tools. Immunohistochemistry is crucial for detecting biomarkers in cancer and other diseases, thus aiding in precise diagnosis and treatment planning. According to data published by the World Health Organization (WHO), in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths. The estimated number of people who were alive within 5 years following a cancer diagnosis was 53.5 million. About 1 in 5 people develop cancer in their lifetime, and approximately 1 in 9 men and 1 in 12 women die from the disease. This surge is aptly met by the key players by introducing more effective products and services. For instance, in April 2024, Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ESR1 Mutation Detection Kit. The assay expands the company's Droplet Digital PCR (ddPCR) offering for the oncology market, where highly sensitive and multiplexed mutation detection assays aid translational research, therapy selection, and disease monitoring. This is further expected to boost the immunohistochemistry market forecast over the coming years.
Significant Technological Advancement
The growing technological innovations in microscopy, staining techniques, and digital imaging enhance the effectiveness and efficiency of immunohistochemistry procedures, thereby making it a preferred method for detailed tissue analysis. For instance, in May 2023, BD (Becton, Dickinson, and Company), a leading global medical technology company, announced the worldwide commercial launch of a new world sales sorting instrument offering two breakthrough technologies that enable researchers to uncover more detailed information about sales that were previously invisible in traditional flow cytometry experiments. With BD CellView Image Technology, researchers can see detailed microscopic images of individual cells and sort at high speeds based on visual characteristics to confirm insights in real time. With BD SpectalFX Technology, researchers can achieve full spectrum cell sorting, coupled with expanded performance enabled by a new modular optical architecture and system-aware algorithms, to perform high parameter experiments within a simplified workflow.
Rising Focus on Personalized Medicine
The increasing shift toward personalized medicine, especially in oncology, is driving the need for immunohistochemistry to identify specific molecular targets and tailor treatments to individual patient profiles, thus improving therapeutic outcomes. For instance, in June 2023, Thermo Fisher Scientific, the world leader in serving science, announced the launch of Gibco OncoPro Tumor Roid Culture Medium Kit, the first commercially available culture medium specifically developed for the expansion of patient-derived tumoroids, or cancer organoids, from multiple cancer indications. Similarly, in January 2023, Apollo Cancer Center, Bengaluru, launched India's first AI Precision Oncology Center (POC) in a significant move that will substantially enhance the quality of oncology care. The Center will help the oncologists, patients, and caregivers to arrive at the best possible results in a time-bound manner the enormous possibilities offered by AI. This is influencing the immunohistochemistry market revenue across the globe.
The publisher provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2026-2034. Our report has categorized the market based on product, application, and end-use.
Antibodies accounts for the majority of the market share
The increasing need for disease diagnosis and research, especially cancers and infectious diseases is elevating the demand for specific antibodies. The rising innovations in antibody engineering improve specificity and sensitivity, enhancing diagnostic accuracy. The expanding biomedical research necessitates diverse antibodies for detailed cellular and molecular studies. Personalized treatment approaches require precise biomarker identification, boosting the use of targeted antibodies. For instance, in August 2023, Regeneron Pharmaceuticals, Inc. announced that the Biomedical Advanced Research and Development (BARDA)authority has agreed with Regeneron to support clinical development, clinical manufacturing, and the regulatory licensure process of on next-generation COVID-19 monoclonal antibody therapy for the prevention of SARS-CoV-2 infection.
Diagnostics holds the largest share of the industry
The increasing cases of cardiovascular, infectious diseases, cancer, autoimmune, nephrological conditions, and diabetes necessitate advanced diagnostic methods. In line with this, the enhancing focus on personalized treatment plans based on specific biomarkers detected through immunohistochemistry. Significant improvements in staining techniques and emerging technologies improve the accuracy and efficiency of disease diagnosis. The growing research activities require detailed cellular analysis, promoting the use of immunohistochemistry in understanding disease mechanisms and pathology. This is further driving the demand for diagnostics in the immunohistochemistry market growth.
Hospitals and Diagnostic Laboratories represents the leading market segment
The rising rates of chronic diseases particularly cancers, are driving the demand for precise diagnostic tools such as immunohistochemistry to accurately identify and classify disease states. Significant innovations in digital imaging systems and staining techniques enhance the diagnostic capabilities and throughput of immunohistochemistry, making it more appealing for clinical settings. The rising focus on adherence to high quality and regulatory standards in diagnostic processes necessitates reliable techniques like immunohistochemistry. The increasing investments in healthcare infrastructure and diagnostic services boost the adoption of advanced diagnostic methods, such as immunohistochemistry, in both developed and emerging markets.
North America leads the market, accounting for the largest immunohistochemistry market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for immunohistochemistry.
The rising cases of cancer and other chronic conditions are driving the demand for precise diagnostic methods like immunohistochemistry to identify biomarkers for effective treatment which is influencing the market growth across the region. The well-established healthcare facilities and robust funding research and development (R&D) are facilitating the adoption of advanced diagnostic technologies. According to the data from the National Library of Medicine, in 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. Cancer mortality continued to decline through 2021, averting over 4 million deaths since 1991 because of reductions in smoking, earlier detection for some cancers, and improved treatment options in both adjuvant and metastatic settings.